TY  - GEN
AU  - Matito, A.
AU  - Escribese, M. M.
AU  - Longo, N.
AU  - Mayorga, C.
AU  - Luengo-Sanchez, O.
AU  - Perez-Gordo, M.
AU  - Matheu, V
AU  - Labrador-Horrillo, M.
AU  - Pascal, M.
AU  - Seoane-Reula, M. E.
AU  - Soc Espanola Alergologia & Inmunol
PY  - 2021
DO  - 10.18176/jiaci.0675
SN  - 1018-9068
UR  - https://hdl.handle.net/10668/24473
T2  - Journal of investigational allergology and clinical immunology
AB  - The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level to >20% + 2 ng/mL within...
LA  - en
PB  - Esmon publicidad s a, dept allergy & clin immunol, clin univ navarra
KW  - Anaphylaxis
KW  - &nbsp
KW  - Antimediator therapy
KW  - &nbsp
KW  - Mast cell activation syndrome
KW  - &nbsp
KW  - Mast cell mediator release-related symptoms
KW  - &nbsp
KW  - Tryptase
KW  - Indolent systemic mastocytosis
KW  - European competence network
KW  - Serum tryptase
KW  - Peripheral-blood
KW  - Venom immunotherapy
KW  - Bone-marrow
KW  - Human skin
KW  - Kit d816v
KW  - Anaphylaxis
KW  - Disorders
TI  - Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview
TY  - review
VL  - 31
ER  -